QUECTEL-WIRELESS
18.3.2024 14:01:29 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces that, according to a recent milestone report by Finite State, an independent third-party cybersecurity firm, nearly 95% of all Quectel modules shipped to the United States since the beginning of 2022 have industry-leading security scores based on penetration testing and binary analysis by Finite State.
The report highlights a notable enhancement in Quectel's security position, expanding the number of modules tested and with scores across the tested modules improving from an average of 33 to 18, up from an average of 62 to 24 in previous testing. This represents a substantial improvement, as both the initial and revised scores significantly surpass the industry average of 98 with the lowest (best) score of 10. Further, the number of and severity of vulnerabilities Finite State did identify in Quectel products or modules are significantly less than the industry standard and revealed a very limited attack surface. Those issues Finite State did discover have been quickly remedied by Quectel.
This advanced phase of testing leverages Finite State's security technologies and expertise to conduct an exhaustive third-party evaluation of Quectel's modules. The advanced testing encompasses an array of sophisticated security assessments designed to fortify Quectel's modules against the evolving landscape of cyber threats, including binary analysis of numerous Quectel products and both penetration testing and binary analysis of several Quectel cellular modules.
"Entering this next phase of security testing with Finite State underscores our relentless pursuit of the highest security standards for our products," stated Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "Our continued collaboration is a reflection of our commitment to exceed industry security expectations, ensuring our customers benefit from the most secure and reliable communication modules available – tested and verified by one of the most trusted US cyber security firms. We’re thrilled that the latest report from Finite State demonstrates our commitment and progress."
The continued integration of Finite State into Quectel’s transparency and security program reaffirms Quectel’s commitment to pioneering unparalleled security practices in the IoT and telecommunications sectors. Quectel has made a measurable improvement in key areas such as the security health of the code, the sophistication of the vulnerability management process, and the transparency of its software supply chain.
The program is strategically designed with three key goals to address the pressing issues in cybersecurity today:
- Implementing the Finite State Platform into Quectel's DevSecOps procedures, which enhances firmware binary analysis, manages vulnerabilities efficiently, and offers specific recommendations for remediation.
- Developing and sharing Software Bill of Materials (SBOM) and Vulnerability Exploitability Exchange (VEX) documents for each of Quectel's products, which promotes a transparent environment and provides critical insights into the software components of Quectel's devices along with any vulnerabilities they may contain.
- Conducting comprehensive manual penetration tests by Finite State's expert Red Team, which augments automated testing methods and delivers detailed security evaluations for Quectel's product line.
Matt Wyckhouse, CEO of Finite State, commented, "Progressing to this next phase of security testing demonstrates Quectel’s commitment to leading the industry with transparent, rigorous cybersecurity practices. Quectel's willingness to subject their products to such rigorous scrutiny is commendable and sets a new industry standard to further safeguard the IoT ecosystem."
The outcome of this continued engagement is anticipated to enhance the security framework of Quectel's modules and inspire a shift towards more rigorous security standards across the telecommunications industry. Quectel is dedicated to sharing insights and best practices gleaned from this process, contributing to a safer, more secure digital future.
In addition to the activity with Finite State, Quectel is actively pursuing collaboration with multiple standards-setting organizations to enhance and commit to a more rigorous set of security requirements. This initiative aims to achieve key security certifications from both industry and governmental bodies, underlining Quectel's dedication to advancing security standards within the sector.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318703729/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
